
Sign up to save your podcasts
Or


In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly.
She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.
You’ll also hear strategies to help patients overcome cost barriers, improve adherence, and understand the importance of regular follow-up.
Whether you’re supporting patients at the pharmacy counter or staying current on HIV prevention, this episode delivers timely insights for pharmacy teams and other healthcare professionals.
This is an excerpt from our September 2025 Pharmacy Essential Updates continuing education webinar series.
******
CE Information:
TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.
Claim Credit
******
Clinical Resources from Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:
Don’t miss out! Subscribe today to stay ahead.
10% off a new or upgraded subscription with code cc1025 at checkout.
🎓 Student free version of Pharmacist’s Letter.
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
By TRC Healthcare5
33 ratings
In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly.
She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.
You’ll also hear strategies to help patients overcome cost barriers, improve adherence, and understand the importance of regular follow-up.
Whether you’re supporting patients at the pharmacy counter or staying current on HIV prevention, this episode delivers timely insights for pharmacy teams and other healthcare professionals.
This is an excerpt from our September 2025 Pharmacy Essential Updates continuing education webinar series.
******
CE Information:
TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.
Claim Credit
******
Clinical Resources from Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:
Don’t miss out! Subscribe today to stay ahead.
10% off a new or upgraded subscription with code cc1025 at checkout.
🎓 Student free version of Pharmacist’s Letter.
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.

90,964 Listeners

38,791 Listeners

699 Listeners

496 Listeners

47 Listeners

299 Listeners

262 Listeners

3,351 Listeners

1,147 Listeners

728 Listeners

374 Listeners

57,886 Listeners

38 Listeners

10,789 Listeners

6 Listeners

0 Listeners